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Abstract 
Background 
The burden of pneumonia continues to be substantial, particularly amongst the poorest in 
global society. We describe here the trends for UK pneumonia R&D investment and 
published outputs, and correlate with 2013 global mortality.  
Methods 
Data related to awards to UK institutions for pneumonia research from 1997 to 2013 were 
systematically sourced and categorised by disease area and type of science. Investment 
was compared to mortality figures in 2010 and 2013 for pneumonia, tuberculosis and 
influenza. Investment was also compared to publication data.  
Results 
Of all infectious disease research between 2011-2013 (£917.0 million), £28.8 million (3.1%) 
was for pneumonia. This was an absolute and proportionate increase from previous time 
periods. Translational pneumonia research (33.3%) received increased funding compared 
with 1997-2010 where funding was almost entirely preclinical (87.5%, here 30.9%), but high-
burden areas such as paediatrics, elderly care and antimicrobial resistance received little 
investment. Annual investment remains volatile; publication temporal trends show a 
consistent increase. When comparing investment to global burden with a novel ‘investment 
by mortality observed’ metric, tuberculosis (£48.36) and influenza (£484.21) receive 
relatively more funding than pneumonia (£43.08), despite investment for pneumonia greatly 
increasing in 2013 compared to 2010 (£7.39). Limitations include a lack of private sector 
data and the need for careful interpretation of the comparisons with burden, plus 
categorisation is subjective.  
Conclusions 
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There has been a welcome increase for pneumonia funding awarded to UK institutions in 
2011-2013 compared with 1997-2010, along with increases for more translational research. 
Published outputs relating to pneumonia rose steadily from 1997-2013. Investment relative 
to mortality for pneumonia has increased, but it remains low compared to other respiratory 
infections and clear inequities remain. Analyses that measure investments in pneumonia can 
provide an insight into funding trends and research gaps. 
Keywords – pneumonia; pneumococcal; investments; financing; policy; bibliometrics; 
publications 
Highlights 
 Pneumonia has historically received little research funding in the UK 
 Pneumonia-related funding is increasing, particularly in translational research 
 Compared to global burden, pneumonia remains poorly-funded compared to 
influenza and tuberculosis 
Research in context 
Pneumonia continues to be a high-burden illness around the globe. This paper shows that 
although research funding is increasing in the UK (between 1997 and 2013), it remains 
poorly funded compared to other important respiratory infectious diseases such as 
tuberculosis and influenza. Publications about pneumonia have been steadily increasing 
over time, indicating continuing academic and clinical interest in the topic. Though global 
mortality of pneumonia is declining, it should still be an area of high priority for funders, 
policymakers and researchers.  
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Introduction 
Despite documented complexities with epidemiological definitions and clinical diagnosis,1 the 
global burden of pneumonia, including healthcare-associated and ventilator-associated 
pneumonia, clearly remains significant. Estimates from the Global Burden of Disease Study 
2013 (GBD 2013) suggested that although mortality from the main pneumonia-causing 
pathogens was decreasing worldwide, there were still at least 785 000 deaths globally from 
pneumococcal pneumonia, respiratory syncytial virus and Haemophilus influenzae 
pneumonia in 2013 with much of this burden in low- and middle-income countries,2 although 
other analyses considered mortality to be greater.3 In GBD 2013 figures, there were a further 
105 000 deaths from influenza, where pneumonia is a significant secondary complication 
from primary infection, and an estimated 2 million deaths from lower respiratory tract 
infections of unknown aetiology.2 The GBD study also attributed 76.7 million disability-
adjusted life-years (DALYs) to pneumonia and pneumococcal disease in 2010, again with 
the poorest sectors of society bearing the majority of this burden.4 Though there is an 
increasing prevalence of non-communicable disease and injuries in middle and lower-
income countries,2 projections from the World Health Organization (WHO) estimate deaths 
from lower respiratory tract infections will remain among the top 4 leading causes of deaths 
in 2015 and 2030.5   
Part of the solution to overcoming these challenges is to invest in research. The UK is 
consistently rated among the top three investors in neglected disease research,6 and UK-
based authors are generally prolific at contributing to the published evidence base.7 Thus the 
activity of UK institutions is likely to be of significant national and international importance.  
The Research Investments in Global Health study (ResIn, www.researchinvestments.org) 
has previously reported on infectious disease research investments awarded to UK 
institutions between 1997 and 2010,8 also specifically highlighting the limited and fractured 
nature of pneumonia and pneumococcal research.9,10 There is a paucity in the systematic 
tracking of global investments in health research and development (R&D), with noted 
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mismatches between the global burden of pneumonia and research investment,11 and only 
one study of limited scope highlighting product and technology-related R&D of bacterial 
pneumonia in low-income settings.12  
We present an update to the ResIn study, covering awards for pneumonia and 
pneumococcal-research from 2011-2013, with reference to previously published data from 
1997-2010 for context. We highlight the trends in both total investment and temporal drift in 
funding by type of science. Furthermore, we compare investment against global mortality of 
disease and describe bibliometric trends for pneumonia-related publications as a surrogate 
of research output. We discuss some clear challenges and evidence gaps, and review 
potential ways forward.  
 
Methods 
Our methods for the analysis covering 1997-2010 are described in detail elsewhere,8,10 and 
have been updated for the 2011-2013 analyses.  
Data collection 
We systematically sourced information on funding decisions from the major public and 
philanthropic funding bodies for infectious disease research 
(http://researchinvestments.org/about-the-study/study-methodology/). Private sector 
investment is not included due to insufficient information in the public domain. Data was 
obtained either by searching online for the institution’s portfolio of awards, or requested 
directly from the funder.  
Data categorisation and handling 
The study team identified the infection-related awards led by a UK institution and 
categorised them by disease area, by specific pathogen and by type of science according to 
their position along the R&D value chain. R&D categories were: preclinical research, phase 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
6 
 
I-III trials, intervention and product development studies, translational (previously referred to 
as implementation and operational research), and cross-disciplinary awards. The cross-
disciplinary category has been newly created for the 2011-2013 analysis, reflecting the 
notable increase in the number of studies with significant components covering two distinct 
types of science. We have not yet retrospectively applied this new category to the 1997-
2010 dataset though do not anticipate revisions to greatly impact on observed trends in 
investment. Further detail on data categorisation is available on the study website, alongside 
the full list of included funders and the search keywords used. Information collected on each 
award included study title and abstract (where available), the lead institution and principal 
investigator, funder, year of award and total funding awarded. As per previous analyses,8 
and similar to approaches recommended by others,13 awards originating from an 
international funder were converted to UK pounds using the mean exchange rate in the year 
of the award. All awards were adjusted for inflation and reported in 2013 UK pounds.  
Each study was categorised by author MGH. Awards for pneumonia and pneumococcal-
related research are included here. There were random checks by at least two other 
individuals on 20% samples of the data to reduce observer error, with differences reported 
and corrected, and any remaining differences settled by consensus. Datasets were also sent 
out to all authors for review and comment.  
Data analysis 
Burden data was sourced from the GBD study.2,14 UK investment and global mortality for 
pneumonia, tuberculosis and influenza was analysed by comparing the sum funding across 
2005-2009 with 2010 burden, and funding across 2008-2012 with 2013 burden. Findings 
were reported as an ‘investment by mortality observed’ metric. The dataset was assembled 
in Microsoft Excel 2013 and Stata (V13) was used for further statistical analysis. Spearman's 
rank correlation coefficient (rho) was used to assess correlation. 
Bibliometrics 
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The publications database Scopus® (http://www.scopus.com/) was used to search for 
publications incorporating the keywords ‘pneumonia’ or ‘pneumococcal’, published between 
1997 and 2013 and including at least one author affiliated to a UK institution. Search results 
were exported and conditional formatting equations used to identify papers with a UK 
individual listed as first or last author; this was a proxy measure for significant involvement 
from the UK and thus used to compare with funding trends. Since most awards in our 
dataset are either less than one year, or between two and three years in duration, a likely 
publication yield for each year of investment was calculated by using the total publications in 
the four years after the award, and this produced an ‘investment per publication’ metric. 
Temporal trends, citation numbers and type of publication were also considered. Microsoft 
Excel 2013 and 2011 was used to assemble the bibliometrics dataset, and Graphpad Prism 
6 (http://www.graphpad.com/scientific-software/prism/) produced the figures.  
 
Results 
Total research funding for all infectious diseases awarded to UK institutions between 2011-
2013 was £917.0 million across 1232 awards (Table 1). Of this, £145.2 million (15.8%) and 
219 awards (17.8%) were related to respiratory infections. Pneumonia and pneumococcal 
research received £28.8 million (3.1% of total and 19.9% of respiratory infections funding) 
across 35 awards (2.8% of total and 16.0% of respiratory infections) (Table 1). By 
comparison across 2011-2013, tuberculosis received £71.1 million (7.8% of total and 49.0% 
of respiratory infections funding) from 83 awards (37.9% of respiratory infections) and 
influenza received £39.1 million (4.3% of total and 26.9% of respiratory infections funding) 
across 53 awards (24.2% of respiratory infections).  
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Table 1. Summary of investment information relating to infectious diseases and pneumonia research 2011-2013 
 
1997-2010 2011-2013 
Disease Number 
of 
awards  
Percentage 
of all 
respiratory 
infection or 
pneumonia 
research 
Total funding, 
£ 
Percentage 
of all 
respiratory 
infection 
or 
pneumonia 
research 
Number 
of 
awards 
Percentage 
of all 
respiratory 
infection or 
pneumonia 
research 
Total 
funding, £ 
Percentage 
of all 
respiratory 
infection 
or 
pneumonia 
research 
Mean  
award, £ 
(SD) 
Median award, £  
(IQR) 
 
                    
All Infectious 
disease 
6165
+
 n/a 2,807,982,764
+
 n/a 1232 n/a 916,960,747 n/a 
744286 
(1360777) 
315918 (156283-
779794) 
All respiratory 
infectious 
disease 
1010
+
 n/a 410,732,999
+
 n/a 219 n/a 145,182,110   
662932 
(1104659) 
319019 (170095-
726046) 
 Pneumonia 102
+
 10.1% 27,788,770
+
 6.8% 35 16.0% 28,849,125 19.9% 
824260 
(1340046) 
335210 (196000-
642463) 
   Pneumococcal 26 25.5% 4,417,895 15.9% 12 34.3% 8,944,883 31.0% 
745406 
(1207254) 
412769 (261084-
647062) 
 
                    
Disease areas 
and products* 
                    
 
                    
Antimicrobial 
resistance 
12 11.8% 2,899,479 10.4% 1 2.86% 4,218 0.01% n/a n/a 
Diagnostics 5 4.9% 335,993 1.2% 3 8.57% 6,814,845 23.62% 
2271615 
(3624003) 
319019 (42617-
6453209) 
Geriatrics 1 1.0% 7,933 0.0% 0 n/a 0 n/a n/a n/a 
Global health 12 11.8% 4,626,308 16.6% 8 22.86% 17,437,921 60.45% 
2179740 
(2241692) 
1039549 
(598711-
3651835) 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
9 
 
Healthcare-
associated 
infections 
2 2.0% 313,651 1.1% 2 5.71% 361,636 1.25% n/a n/a 
HIV 7 6.9% 1,397,599 5.0% 1 2.86% 404,523 1.40% n/a n/a 
Paediatrics 9 8.8% 1,733,415 6.2% 2 5.71% 3,331,750 11.55% n/a n/a 
Therapeutics 4 3.9% 1,050,241 3.8% 3 8.57% 1,166,680 4.04% 
388893 
(235729) 
319019 (196000-
651661) 
Vaccinology 9 8.8% 5,364,389 19.3% 8 22.86% 10,371,078 35.95% 
1296385 
(1447016) 
604472 (443647-
1757426) 
 
* percentages in “Disease areas and products” are calculated as a fraction of all pneumonia research rather than all respiratory infection 
research. Because awards can cover more than one disease area or product category, the sum of these column percentages may exceed 
100%.  
+ Data published previously but here corrected for 2013 inflation 8,10 
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These findings represent an approximately three-fold  total and proportional increase from 
1997-2010, where we reported that pneumonia-related research represented 6.6% of all 
respiratory infections and 1.1% of all infectious disease research funding.10 Total funding for 
pneumonia across the three-year period of 2011-2013 is greater than total funding across 
the fourteen year period of 1997-2010, with mean annual pneumonia funding in this update 
time period is £9.6 million compared with £2.0 million previously. The mean annual number 
of awards has increased slightly from 7 to 12 and the median award size has increased from 
£ 137389 to £ 335210 (Interquartile range £ 196000- 642463). Similarly, the total annual 
investment in infectious disease research has increased by 64.6% in the period 2011-2013, 
compared with 1997-2010, despite similar numbers of awards. Investment and year were 
moderately correlated (rho 0.6152, p=0.0086), research output and year were strongly 
correlated (rho 0.9798, p=0.0001) and investment was moderately correlated with research 
output (rho 0.6107, p=0.0092). 
Of the 35 pneumonia studies, 12 focused on Streptococcus pneumoniae. Eight awards 
focused on vaccine research, with 3 awards each concerned with diagnostics and 
therapeutics. Two awards had a specific focus on paediatrics, with no awards focusing on 
elderly care. Eight awards were clearly related to global health (Table 1). Temporal trends, 
building on previously published data,9 show an inconsistent long-term approach but 
significant increases in investment in recent years (Figure 1). 
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Figure 1. Sum research investment and publications for pneumonia, by year 
Previously, Wellcome Trust was the leading funder of UK-awarded pneumonia research 
(44.8% of the total 1997-2010, now 15.9%).10 In this update (Table 2), the European 
Commission provided the largest proportion of pneumonia research investments (31.2%) 
through 6 large awards, of which 5 were preclinical, amounting to £9.2 million; during 1997-
2010 they supported just two studies. The second largest contribution was from the Bill & 
Melinda Gates Foundation, which provided £7·4 million (26.6%) of investment across 5 
awards, 4 of which were translational; during 1997-2010 there were no awards from the Bill 
and Melinda Gates Foundation to UK institutions for pneumonia.  
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Table 2. Pneumonia research investments 2011-2013, by funder 
Disease 
Number 
of awards 
2011-2013 
Percentage 
of total 
Total 
funding 
2011-2013 
Percentage 
of total 
Mean  award 
£ (SD) 
Median award 
£  (IQR) 
All pneumonia investment 35  £28,849,125  824,260 
(1,340,046) 
335,210 
(196,000-642,463) 
BBSRC 2 5.71% £1,060,870 3.68% n/a n/a 
Bill and Melinda Gates 
Foundation 
5 14.3% £7,360,368 25.51% 1,472,074 
(1,767,709) 
656,391 
(603,102-
1,422,707) 
European Commission 6 17.1% £9,185,732 31.84% 1,530,955 
(2,533,903) 
188,121 
(170,095-
2,101,297) 
Medical Research Council 9 25.7% £5,617,685 19.47% 624,187 
(821,816) 
273,432 
(235,476-564,749) 
National Institute for Health 
Research 
2 5.71% £941,053 3.26% n/a n/a 
Wellcome Trust 8 22.9% £4,592,214 15.92% 574,026 
(622,481) 
363,534 
(302,855-485,644) 
Other 3 8.57% £91,202 0.32% 30,400 
(22,691) 
42,617 
(4,218-44,367) 
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There have been changes in pneumonia investment trends when considering the type of 
science along the R&D pipeline. Previously, 87.5% of the funding was devoted to preclinical 
research.9 Across 2011-2013 (Table 3, Figure 2), preclinical research now accounted 30.9% 
of investment, with comparable amounts awarded to intervention and product development 
studies (32.7%) and translational research (33.3%).   
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Table 3. Pneumonia research investments 2011-2013, by type of science 
Disease 
Number of 
awards 
2011-2013 
Percentage 
of total 
Total 
funding 
2011-2013 
Percentage 
of total 
Mean  award 
£ (SD) 
Median award 
£  (IQR) 
All pneumonia investment 35  £28,849,125  824,260 
(1,340,046) 
335,210 
(196,000-642,463) 
Pre-clinical 22 62.9% £8,917,385 30.9% 405,335 
(424,894) 
280,062 
(188,121-564749) 
Phase I-III 1 2.86% £554,959 1.92% n/a n/a 
Intervention and product 
development 
3 8.57% £9,426,000 32.7% 3,142,000 
(3,144,551) 
2776,792 
(196,000-
6,453,209) 
Translational 8 22.9% £9,615,570 33.3% 1,201,946 
(1,514,565) 
530,457 
(235,154-
1,757,426) 
Cross-disciplinary 1 2.86% £335,210 1.16% n/a n/a 
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Figure 2. Proportion of research investment for pneumonia R&D, by year and by type of 
science.  
* 1997-2010 data previously published.9  
 
 The ‘investment by mortality observed’ metric for pneumonia is much greater in 2013 
(£43.08) than 2010 (£7.39), though remains less than tuberculosis (£48.36) and influenza 
(£484.21) across both years (Table 4).  
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Table 4. Relationship between research investment and mortality for pneumonia, tuberculosis and influenza.  
* Pneumonia mortality data includes Pneumococcal pneumonia / H. influenzae type b pneumonia / Respiratory Syncytial Virus pneumonia 
Infection Year 
Numbers of 
deaths 
Investment 5 
years beforehand 
R&D investment 
per death 
Pneumonia* 2010 2,319,100 £17,146,396 £7.39 
  2013 784,600 £33,802,448 £43.08 
Tuberculosis 2010 1,196,000 £86,338,770 £72.19 
  2013 1,290,300 £62,399,586 £48.36 
Influenza 2010 507,900 £51,991,733 £102.37 
  2013 105,000 £50,841,831 £484.21 
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 There were 8400 publications related to pneumonia that contained a first and/or last UK-
affiliated author. Temporal trends show a steady increase in publication numbers per year 
between 1997 and 2013 (Figure 1), with the majority of publications being original articles 
(4771, 56.8%) or reviews (1759, 20.9%) (Figure 3a). In 1997, there were 250 publications, 
and in 2013 there were 792, a more than three-fold increase. The ‘R&D investment per 
publication’ metric demonstrated great variability year on year, with a peak of £2395 in 2005 
and a low of £395 in 2007, and median investment across 1997-2009 of £779 per 
publication (Table 5). Citations of pneumonia publications included in this dataset increased 
over time from 1997 (5874) until 2008 (16862, an increase of almost three-fold) (Figure 3b). 
For comparison, equivalent median investment per publication for tuberculosis was £6335 
(range £1822-15824), and £4100 (range £314-20074) for influenza. Tuberculosis publication 
numbers (8194) and temporal trends were broadly similar to that of pneumonia, whilst 
influenza publications (4864) and citations were fewer but with notable increases around the 
time of concerns around the H5N1 strain, and then the H1N1 pandemic strain 
(supplementary information). 
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Table 5. R&D investment for pneumonia and pneumonia-related published outputs 
Year Funding Publications 
Likely 
publication 
yield 
UK pound per 
publication 
1997 £611,493 250 1150 £532 
1998 £1,794,230 250 1250 £1,435 
1999 £896,453 242 1463 £613 
2000 £3,719,166 348 1581 £2,352 
2001 £1,264,689 310 1732 £730 
2002 £1,332,194 350 1902 £700 
2003 £1,853,285 455 1997 £928 
2004 £239,056 466 2069 £116 
2005 £5,431,788 461 2268 £2,395 
2006 £1,851,883 520 2376 £779 
2007 £1,023,629 550 2591 £395 
2008 £3,449,233 538 2868 £1,203 
2009 £5,389,863 660 3000 £1,797 
2010 £1,345,555 628 n/a n/a 
2011 £9,763,953 765 n/a n/a 
2012 £13,853,844 815 n/a n/a 
2013 £5,231,327 792 n/a n/a 
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Figure 3a) Number of publications by year and publication type, b) Number of citations, by 
year and publication type 
 
Discussion 
Annual pneumonia funding was considerably greater in the period 2011-2013 compared to 
the period 1997-2010, yet the increase in number of awards remains modest with the pattern 
of investment appearing to favour larger individual grants (a trend reflected across all 
infectious disease research). There has been a notable shift in the type of science funded, 
which previously was almost entirely devoted to preclinical research but now represents a 
balance of preclinical, intervention and product development, and translational research. 
There are still relatively few studies funded by public and philanthropic institutions that focus 
on tools to control pneumonia such as vaccines, diagnostics and novel therapeutics, and 
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minimal investment specifically for paediatric, elderly care or antimicrobial resistance 
research.  
The European Commission and Bill and Melinda Gates Foundation are now the leading 
funders of pneumonia research awarded to UK institutions (though the MRC and Wellcome 
Trust each contributed the greater number of awards), highlighting an important shift in 
funding policy and advocacy by global health organizations. Compared to global mortality, 
pneumonia R&D funding is improving, as we observe increased investment and decreased 
mortality. Tuberculosis and influenza receive greater R&D investments in absolute terms and 
also relative to their attributable burden of disease.  Bibliometric trends for pneumonia show 
a broadly steady annual increase from 1997 to 2013, but with great variability when 
assessed using the ‘R&D investment per publication’ metric as applied here. The similar 
temporal increase in citation numbers could be taken to indicate that one use of the 
pneumonia publications is to continuously inform the development of other published 
outputs, some of which will have resulted from the funding analysed here; however, 
publications have variable impact and further bibliometrics should be developed to evaluate 
use of publications in informing other areas of knowledge such as policy development. 
Linkage between individual investment and their published outputs would be one area to 
develop to more closely map the extent of any relationship between them.  
The increase in investment in this high-burden and priority area is clearly positive. It remains 
to be seen whether the trend of funding consortia, programme grants and other large project 
grants, particularly in areas of research beyond preclinical science, will reap the benefits of 
increased impact and ultimately provide a greater contribution to the reduction of disease 
burden than has been observed so far. The burden of pneumonia is decreasing, although it 
remains a focus of policy and advocacy groups such as the WHO and Bill & Melinda Gates 
Foundation,15,16 and accelerating the reductions in incidence will arguably require a 
sustained increased level of investment in both research and implementation. The lack of 
phase I-III clinical trials is concerning, though this is an area where the private sector 
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traditionally invests, at least in high-income settings. Investments in innovative products with 
the potential to impact on health would be a pragmatic approach for future research, though 
the roll-out of research and any subsequent implementation must be appropriate. The 
European and Developing Countries Clinical Trials Partnership and the Global Fund have 
been influential in this area in particular for HIV, tuberculosis and malaria. Operational 
research is important to optimise the distribution and accessibility of pneumonia treatments 
such as antibiotics in the community and oxygen in hospitals, as is the development of new 
vaccines to protect against strains of pneumococcus not covered by the current multivalent 
conjugate vaccines. The Bill & Melinda Gates Foundation has invested significantly in 
research to define the aetiology of pneumonia in children in low-income countries over this 
period.17 As GBD 2013 illustrates,2 the large proportion of lower respiratory tract infections 
with unknown aetiology remains a challenge for many suffering from suspected 
pneumonia.18–20 Rapid point of care tests demonstrating high specificity and sensitivity are 
urgently needed, with a focus on products that are suitable for use in low-income healthcare 
and community settings. Advances in nanotechnology research may yield highly specific 
new assays;21 however, they may emphasise the clinical uncertainty that identifying the 
bacteria does not necessarily mean it is the pathogen causing the illness.20  In terms of 
advocacy, building capacity and attracting increased funding, there may be an opportunity to 
learn from established research communities receiving proportionately greater R&D 
investment, such as those who work on tuberculosis and influenza. The area of pneumonia, 
though large, lacks a single-disease advocacy body to focus attention on the likely returns 
on research investments in this area. Elsewhere, a detailed analysis of research priorities 
suggested that health policy and systems research to improve access and coverage by the 
existing interventions (such as vaccine and therapeutic delivery) were key in the short term, 
as well as epidemiological research to address the most important gaps in knowledge.11 
Antimicrobial resistance is an under-resourced area across all investments for infectious 
disease research,22,23 and pneumonia is no exception. Globally, resistance to S. pneumoniae 
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is increasing. Recent trends have concerned the Centers for Disease Control and Prevention 
(CDC) in the US who made specific reference to this area in their unprecedented 2013 
Threat Report,24 as well as being a focus of the WHO 2014 global report on surveillance.25 It 
is imperative to increase development in the R&D pipeline of novel antibacterial therapies 
active major causes of pneumonia including S. pneumoniae, S. aureus, and K. pneumoniae, 
especially those that are acquired in-hospital, where the pathogens are highly selected for 
resistance. It is also important to broaden the selection of agents to treat viral pneumonia, 
particularly disease caused by influenza, para-influenza and respiratory syncytial virus. The 
economic impact of infectious disease is notoriously difficult to quantify,26 though the annual 
economic burden of pneumonia in Europe has been estimated at €10.1 million,27 and 
treating hospitalised cases of community-acquired pneumonia in the US results in mean 
costs of $15385 per patient across over one million annual patient episodes.28  
There are recognised difficulties with any comprehensive analysis of R&D data,13 and the 
limitations of this study have been described in detail previously.8,10 An important point to 
reiterate here is the lack of private sector data. Gaps in knowledge here will likely mask the 
true total investments for, in particular, preclinical research and clinical trials for key 
advances in vaccine, diagnostic and therapeutic development. There may also be funds 
dedicated to respiratory infectious disease in any of the three NIHR-funded Biomedical 
Research Units with a respiratory focus that may not be listed as separate awards and thus 
not included here. We do not take into account the proportion of each award dedicated to 
each of the categories that may be applied to a single study. We also do not investigate the 
distribution of funds from the lead institution to any collaborating partners, nor do we take 
account of funding intended for covering indirect or estate costs or any overheads. A basic 
sensitivity analysis suggests that the Research Councils introduction of full economic costing 
in 2004 has not greatly skewed the size of awards and the volatility in total and temporal 
trends remain when considering pneumonia funding with and without BBSRC and MRC 
data, though there may be implications for other areas of infectious disease research. The 
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impact of the stochastic nature of research funding is also difficult to quantify. We rely on 
study titles and abstracts to provide specific mention of pneumonia or alternatively clearly 
imply the study is related to pneumonia.  It is difficult to quantify the level of funding missed 
in our data collection exercise, however this is mitigated by the fact that all major public and 
philanthropic funders of UK research, and dozens more awarding bodies, have supplied 
data. The metric development for investment by mortality and published outputs needs 
further development and validation, and application to other disease areas to allow direct 
comparisons.  
Despite recent sum and relative increases, funding available for pneumonia research 
remains disproportionately low, when compared with the global burden of disease. There are 
no sustained comprehensive efforts to track global pneumonia-related R&D investments, 
and this should be tackled in order to allow simpler identification of research and evidence 
gaps. Other countries, particularly the US which is the largest investor in global health, have 
pneumonia portfolios that may cover areas where the UK is not investing. A multi-country 
analysis, similar to that carried out in the UK by the ResIn study, is warranted to provide a 
comprehensive global investment surveillance system for health R&D. A more detailed 
breakdown of bibliometrics trends and linkage to investments data, plus identification of 
additional measures of research impact, across all infectious diseases and non-
communicable disease, would allow for greater scrutiny of how research investments are 
allocated and how well they perform, openly assess accountability, and ultimately allocate 
limited resources wisely.  
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